ArticleBiomedical chromatography : BMC2026
Microbial Fermentation Reduces Xerostomia-Related 5-Demethylnobiletin in Aurantii Fructus: A Chromatographic and Pharmacological Evaluation.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aurantii Fructus is a widely used herb with dual-purpose food-medicine applications; however, prolonged consumption may lead to the development of xerostomia. Although traditional processing methods of Aurantii Fructus can mitigate this adverse effect, they are characterized by cumbersome procedures and significant time demands, and the key constituents and underlying mechanisms responsible for symptom alleviation remain insufficiently defined. In the present study, we propose an innovative microbial fermentation approach (FY) for processing Aurantii Fructus, which markedly streamlines the workflow and shortens the overall processing duration. Notably, FY significantly reduces the content of 5-demethylnobiletin, a xerostomia-related component, in Aurantii Fructus and ameliorates dry mouth symptoms, which is associated with the modulation of aquaporin-5 (AQP5) protein expression in the submandibular gland. This microbial fermentation strategy not only improves processing efficiency and reduces time and cost but also helps elucidate the key constituents and mechanisms involved in mitigating dry mouth, thereby providing a new direction for the optimized processing and broader application of Aurantii Fructus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.